Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.

Author: AaproMatti, CelioLuigi, JordanKarin, KarthausMeinolf, RoelandEric, ScottéFlorian

Paper Details 
Original Abstract of the Article :
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with guideline-recommende...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720881/

データ提供:米国国立医学図書館(NLM)

Netupitant-Palonosetron (NEPA) for Preventing Chemotherapy-Induced Nausea and Vomiting: A New Oasis in the Desert of Cancer Treatment

Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, often described as a desert of discomfort and distress. This study examines the role of netupitant-palonosetron (NEPA) in preventing CINV.

The researchers reviewed the evidence from clinical trials and real-world practice, highlighting NEPA's potential as a convenient and effective antiemetic treatment for CINV. The study found that NEPA, in combination with dexamethasone, offered a promising approach to preventing CINV, particularly for patients receiving highly emetogenic chemotherapy. It's like discovering a new and effective oasis in the desert of cancer treatment, providing relief and support for patients facing this challenging side effect.

Easing the Burden of CINV

This research provides valuable insights into the use of NEPA for preventing CINV. The findings suggest that this combination antiemetic could significantly improve the quality of life for cancer patients undergoing chemotherapy. It's a step towards creating a more comfortable and manageable journey through the desert of cancer treatment.

Navigating the Desert of Cancer Treatment

Cancer treatment can be a challenging and stressful experience, and this study emphasizes the importance of managing side effects like CINV. NEPA offers a potential new tool to help patients navigate this challenging terrain and maintain their quality of life during treatment. It's like finding a reliable source of water and shade in the desert, offering relief and comfort along the journey.

Dr.Camel's Conclusion

This study explores a potential new oasis in the desert of cancer treatment, focusing on the role of NEPA in preventing CINV. It underscores the importance of managing side effects to improve patient well-being and quality of life during this challenging journey. It's a testament to the ongoing efforts to find new and effective ways to support patients navigating the desert of cancer treatment.

Date :
  1. Date Completed 2022-09-23
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

35570542

DOI: Digital Object Identifier

PMC9720881

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.